Alkermes clinical trials we track

Check company identity source

Phase 3 6 trials

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg, ALKS 2680, 4mg and 2 moreRecruiting2030-06Estimated

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 100 Weeks. After: Measure: Incidence of Treatment-Emergent Adverse Events Time frame: Up to 248 Weeks.

Planned enrollment increased by 530 participants

Before: 256 participants (planned). After: 786 participants (planned).

Primary completion date changed

Before: Jun 2028. After: Jun 2030.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 80 participants (planned). After: 93 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Nov 2025. After: 11 Nov 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source